Vaccination with Theratope® (STn-KLH) as treatment for breast cancer

References

• Borges E, Wiesmuller K-H, Jung G,Walden P Efficacy of synthetic vaccines in the induction of cytotoxic T-lymphocytes. Comparison of the costimulating support provided by helper T-cells and lipoamino acid. J Irnrnunol. Irnmunother. 36, 215–222 (1993).
   Google Scholar
• Cormier JN, Salgaller ML, Prevette T et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melen A. Cancer Sd. Am. 3(1), 37–44 (1997).
   Google Scholar
• Kantor J, Irvine K, Abrams S et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. Natl Cancer Inst. 84, 1084–1091 (1992).
   Google Scholar
• Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccina-CEA vaccine. J Nat] Cancer Inst. 87, 982–990 (1995).
   PubMed Web of Science ®Google Scholar
• Livingston PO, Wong GYC, Adluri S et al. Improved survival in Stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.Oncol. 12,1036–1040 (1994).
   Google Scholar
• MacLean GD, Reddish MA, Koganty RR et al. Immunization of breast cancer patients using a synthetic Sialy-Tn glycoconjugate plus Detox adjuvant. Cancer I17717711fla Innnunother. 36, 215–222 (1993).
   Google Scholar
• Longenecker BM, Reddish M, Koganty R, MacLean GD. Immune responses of mice and human breast cancer patients following immunization with synthetic Sialy-Tn conjugated to KLH plus Detox adjuvant. Ann. NY Acad. Science 690, 276–291 (1993).
   PubMed Web of Science ®Google Scholar
• •Immune responses elicited by Theratope.
   Google Scholar
• MacLean GD, Reddish MA, Longernecker BM. Antibodies against mucin-associated Sialy-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Irnmunother. 19, 59–68 (1996).
   Google Scholar
• •Antibody response to Theratope associated with clinical outcome.
   Google Scholar
• MacLean GD, Miles DVV, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of Theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. Innnunother. 19, 309–316 (1996).
   Google Scholar
• •Demonstrates the benefits of cyclophosphamide with Theratope in nontranplant trial.
   Google Scholar
• Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 46, 3118–3124 (1986).
   Google Scholar
• Reddish MA, Jackson L, Koganty RR et al. Specificities of antisialy Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycoryugate "14, 549–560 (1997).
   Google Scholar
• Ibrahim N, Murray J. Clinical development of Theratope vaccine. Clin. Breast Cancer 3\(Suppl. 4), 5139—S143 (2003).
   Google Scholar
• Drummer HE, Jackson DC, Brown LE. Modulation of CD4+ T-cell recognition of hemaggutination by carbohydrate side chains located outside a T-cell determinant. Virology192, 287–289 (1993).
   Google Scholar
• Iitzkowitz SH, Bloom EJ, Kokaw WA et al. Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 66, 1960–1989 (1990).
   Google Scholar
• Kobayahsi H, Terao T, Kawashima Y. Serum Sialy-Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Cilia. Oncol. 10, 95–101 (1992).
   Google Scholar
• Miles DVV, Happerfield LC, Smith P et al. Expression of Sialy-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br. J Cancer 70, 1272–1275 (1994).
   PubMed Web of Science ®Google Scholar
• Miles DW, Lineham J, Smith P, Filipe I. Expression of Sialy-Tn in gastric cancer: correlation with known prognostic factors. Br .j Cancer71, 1074–1076 (1995).
   PubMed Web of Science ®Google Scholar
• Kinney AY, Sahin, A, Verno, SW et al. The prognositic significance of Sialy-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer80, 2240–2249 (1997).
   PubMed Web of Science ®Google Scholar
• Von Mensddorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA. An enyme-linked immunoiabsorbent assay for the measurment of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumor Biol. 19, 186–195 (1998).
   Google Scholar
• Jerome K, Barnd D, Bendt KM et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core off a mucin molecuale preferentially expressed by malignant cells. Cancer Res. 51, 2908–2916 (1991).
   PubMed Web of Science ®Google Scholar
• Bung PYS, Madej M, Koganty RR, Longenecker BM. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res. 50, 4308–4314 (1990).
   Google Scholar
• Singhal A, Fohn M, Hakomori SI. Induction of a-N-acetylgalactosamine-0-serineithreonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res. 51, 1406–1411 (1991).
   Google Scholar
• Elgbert KD, Farrar WL. Suppressor cell activity in tumor-bearing mice. I. Dualistic inhibition by suppressor T-lymphocytes and macrophages. J Irnmunol. 120, 1345–1353 (1978).
   Google Scholar
• North RJ, Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. J Exp. Med. 159, 1295–1311 (1984).
   PubMed Web of Science ®Google Scholar
• Yu A, Watts H, Jaffe N, Parkman R. Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma. N Engl. J Med. 297,121–127 (1977).
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Ratiliff TL, McCool RE. Concanavalin A-activated suppressor cell activity in the peripheral blood lymphocytes of urology cancer patients. Nat] Cancer Inst. 65,553–557 (1980).
   Google Scholar
• Bursuker I, North RJ. Suppression of generation of concomitant antitumor immunity bypassively transferred suppressor T-cells from tumor-bearing donors. Cancer Irnmunol. Irnmunther. 19, 215–218 (1985).
   Google Scholar
• Fung PY, Madej M, Kogantry RR, Longenecker BM. Active aspecific immunotherapy of a murine mammary adenocarcainom using a synthertic tumor-associate glycoconjugate. Cancer Res. 50,4308–4314 (1990).
   PubMed Web of Science ®Google Scholar
• Fung PY, Longenecker BM. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res. 51,1170–1176 (1991).
   PubMed Web of Science ®Google Scholar
• Ehrke M, Mihich E, Berd D, Mastrangelo MJ. Effects of anticancer drugs on the immune system in humans. Sern. Oncol. 16, 230–253 (1989).
   PubMed Web of Science ®Google Scholar
• Longenecker MB, Reddish M, Koganty R, MacLean GD. Immune responses of mice and human breast cancer patients following immunization with synthetic Saily-Tn conjugated to KLH plus detox adjuvant. Ann. NY Med. Sci. 690, 279–291 (1993).
   Google Scholar
• •Immune responses to Theratope in the nontransplant setting.
   Google Scholar
• Miles DVV, Towlson KE, Graham R et al. A randomized Phase II study of Sialy-Tn and Detox-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. Cancer74, 1292–1296 (1996).
   Google Scholar
• ••Demonstrates the benefits of intravenouscyclophosphamide combined with Theratope in the nontransplant setting.
   Google Scholar
• Miles D, Papazisis K et al. Rationale for the clinical development of STn-KLH (Theratope®) and anti-MUC-1 vaccines in breast cancer. Cilia. Breast Cancer 3\(Suppl. 4), 5134—S138 (2003).
   Google Scholar
• Miles D, Ibrahim N, Roche H et al. An international randomized Phase III clinical trial of STn-KLH (Theratope) therapeutic cancer vaccine in metastic breast cancer patients. Proceedings of the 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 36 (2003).
   Google Scholar
• ••Phase III Theratope trial in breast cancer.
   Google Scholar
• Ibrahim NK, Murray J, Parker J et al. Humoral immune-response to naturally occurring STn in metastatic breast cancer (MBC pts) treated with STn-KLH Vaccine. Proc. Am. Soc. Clin. Oncol. 22, S174 (2004).
   Google Scholar
• ••Immune response to Theratope inPhase III trial associated with outcome.
   Google Scholar
• Majordomo J, Tres A, Miles D et al. Long- term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STn-KLH vaccine with KLH control in Stage IV breast cancer following front-line chemotherapy. Proc. Am. Soc. Clin. Oncol. 22,1882S (2004).
   Google Scholar
• •• Update on Phase III Theratope trial in breast cancer.
   Google Scholar
• Bowen Yacyshyn MB, Poppema S, Berg A et al. CD69+ and HLADr+ activation antigens on peripheral blood lymphocyte populations in metastatic beast and ovarian cancer patients: correlation with survival following active specific immunotherapy. Int.j Cancer 61,470–474 (1995).
   Google Scholar
• Pichler WJ, Wyss-Cora YT. T-cells as antigen-presenting cells. Irnmunol. Today 15,312–315 (1994).
   PubMedGoogle Scholar
• Reddish MA, MacLean GD, Poppema S, Berg A, Longenecker BM. Pre-immunotherapy serum CA 27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope Sialy-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Irnmunol. Irnmunother. 42,303-309 (1996).
   Google Scholar
• •Immune responses to Theratope associated with outcome.
   Google Scholar
• Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibit human T-cell proliferation which is reversible by IL-2. Nat] Med. 4,43–49 (1998).
   PubMed Web of Science ®Google Scholar
• Storek J, Witherspoon RE Immunological reconstitution after hem poetic stem cell transplant. In: Clinical Bone Marrow and Blood Stem Cell Transplantation. Second Edition. Atkinson K (Ed.). Cambridge, UK, 111–146 (2000).
   Google Scholar
• Holmberg LA, Oparin DV, Cooley T et al. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and Theratope STn-KLH cancer vaccine. Bone Marrow Transpl. 25,1233–1241 (2000).
   PubMed Web of Science ®Google Scholar
• •• Theratope after autologous transplant.
   Google Scholar
• Holmberg LA, Oparin DV, Cooley T, Sandmaier BM. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cacner patients: experience with Theratope vaccine. Clin. Breast Cancer 3, S144 (2003).
   PubMedGoogle Scholar
• ••Update of Theratope after autologoustransplant.
   Google Scholar
• Sandmaier BM, Oparin DV, Holmberg LA et al. Evidence for a cellular immune response against Sialy-Tn in breast and ovarian cancer patients following high-dose chemotherapy, stem cell rescue and immunization with Theratope STn-KLH cancer vaccine. J Irnmunother. 22,54–66 (1999).
   PubMed Web of Science ®Google Scholar
• •Immune response to Theratope after autologous transplant.
   Google Scholar
• Hardy CV, Kihlberg J, Elofsson M, Magnusson G, Unanue ER. Glycopeptides bind MHC molecules and elicit specific T-cell responses. J Irnmunol. 151, 2419–2425 (1993).
   Google Scholar
• Harum JS, Arsequell G, Lelloch AC et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T-lymphocytes. J Exp. Med. 180,734–744 (1994).
   Google Scholar
• Deck B, Elofsson M, Kihlberg J, Unanue ER. Specificity of glycopeptide-specific T-cells. Immurio/. 155,1074–1078 (1995).
   Google Scholar
• Jensen T, Galli-Stampino L, Mouritsen S et al. T-cell recognition of Tn-glycosylated peptide antigens. Eur. j Immunol. 26, 1324–1349 (1996).
   Google Scholar
• Galli-Stampino L, Meinjohanns E, Frische K et aL T-cell recognition of tumor-associated carbohydrates: the nature of the gylcan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res. 57,3214–3222 (1997).
   PubMed Web of Science ®Google Scholar
• Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 92, 1471–1490 (1998).
   Google Scholar
• Mizoguchi H, O'Shea JJ, Longo D et al. Alterations in signal transduction molecules in T-lymphocytes from tumor-bearing mice. Science 258,1795–1798 (1992).
   Google Scholar
• Holmberg LA, Sandmaier B. Theratope vaccine (STn-KLH). Expert Opirr. Biol. Ther. 1(5), 881–891 (2001).
   Google Scholar